FDA to Issue New Guidelines for Cannabis CBD
2023.01.26 14:48
FDA to Issue New Guidelines for Cannabis CBD
By Ray Johnson
Budrigannews.com – On Thursday, the Food and Drug Administration of the United States stated that it needs to create a new framework in order to guarantee the safe use of the well-known cannabis compound CBD in food and supplements. It also stated that it does not intend to issue any new guidelines regarding the use of CBD in these products.
A new cross-agency regulatory framework would be created, according to the health regulator, in collaboration with Congress. Three citizen petitions asking for direction were turned down by the FDA.
Based on the data and studies it reviewed and conducted, the agency stated that the current safety standards for dietary supplements or food additives are not appropriate for cannabidiol.
According to FDA Principal Deputy Commissioner Janet Woodcock, “we have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm.”
Cannabis yields the non-psychoactive compound cannabidiol. The compound’s long-term use has raised a number of safety concerns, including the possibility of liver and male reproductive system harm.
The FDA has primarily focused on food and beverage products that make unsubstantiated health claims in its enforcement of CBD regulations.
The FDA stated that the available data did not demonstrate how CBD products could meet the safety standard for substances in animal food, and that it also did not intend to issue new regulations allowing the compound to be used in animal food.
The agency stated:
“A new regulatory pathway for CBD is required that balances individuals’ desire for access to CBD products with the regulatory oversight required to manage risks.”
Cannabis merchandise, with Jazz Pharmaceuticals (NASDAQ:) excluded Epidiolex, a medication that Plc makes to treat epilepsy, is against the law in the United States on a federal level, though some states permit its use.
